Outlook Therapeutics

(NASDAQ) OTLK

Current Price$0.22

Market Cap$26.72M

Since IPO (2016)-100%

5 Year-99%

1 Year-85%

1 Month-12%

Outlook Therapeutics Financials at a Glance

Market Cap

$26.72M

Revenue (TTM)

$205.53K

Net Income (TTM)

$102.86M

EPS (TTM)

$-1.09

P/E Ratio

-0.20

Dividend

$0.00

Beta (Volatility)

0.95 (Low)

Dividend

$0.00

Beta (Volatility)

0.95 (Low)

Price

$0.22

Volume

36,223

Open

$0.22

Price

$0.22

Volume

36,223

Open

$0.22

Previous Close

$0.22

Daily Range

$0.22 - $0.23

52-Week Range

$0.16 - $3.39

Dividend

$0.00

Beta (Volatility)

0.95 (Low)

Price

$0.22

Volume

36,223

Open

$0.22

Previous Close

$0.22

Daily Range

$0.22 - $0.23

52-Week Range

$0.16 - $3.39

OTLK News

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Outlook Therapeutics

Industry

Biotechnology

Sector

Health Care

Employees

CEO

Robert Charles Jahr, MBA

Website

www.outlooktherapeutics.com

Headquarters

Iselin, NJ 08852, US

OTLK Financials

Key Financial Metrics (TTM)

Gross Margin

-6%

Operating Margin

-287%

Net Income Margin

-500%

Return on Equity

Return on Capital

Return on Assets

-6%

Earnings Yield

-5.00%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$26.72M

Shares Outstanding

120.74M

Volume

36.22K

Avg. Volume

3.58M

Financials (TTM)

Gross Profit

$657.21K

Operating Income

$67.06M

EBITDA

$63.58M

Operating Cash Flow

$51.83T

Capital Expenditure

$3.00

Free Cash Flow

$51.83T

Cash & ST Invst.

$8.08M

Total Debt

$30.19M

Outlook Therapeutics Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q1 2026YOY CHG

Revenue

$1.21M

N/A

Gross Profit

$1.24M

-4198.5%

Gross Margin

1.02%

N/A

Market Cap

$26.72M

N/A

Market Cap/Employee

$1.16M

N/A

Employees

N/A

Net Income

$23.06M

-232.7%

EBITDA

$13.48M

+37.5%

Quarterly Fundamentals

Name

Q1 2026YOY CHG

Net Cash

$28.22M

-11.4%

Accounts Receivable

$114.61K

N/A

Inventory

$0.00

-100.0%

Long Term Debt

$171.99K

-26.2%

Short Term Debt

$36.72M

+19.2%

Return on Assets

-5.64%

N/A

Return on Invested Capital

1.91%

N/A

Free Cash Flow

$14.94T

-136214495.4%

Operating Cash Flow

$14.94T

-136214495.4%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

HOWLWerewolf Therapeutics, Inc.

HOWLWerewolf Therapeutics, Inc.$0.68+9.68%

MDCXMedicus Pharma Ltd. Common Stock

MDCXMedicus Pharma Ltd. Common Stock$0.34+6.69%

IOBTIO Biotech, Inc.

IOBTIO Biotech, Inc.$0.01-27.59%

NRXPNRx Pharmaceuticals, Inc.

NRXPNRx Pharmaceuticals, Inc.$3.08+0.65%

COEPCoeptis Therapeutics, Inc.

COEPCoeptis Therapeutics, Inc.$16.40+0.00%

EQEquillium, Inc.

EQEquillium, Inc.$2.11-1.40%

SPRBSpruce Biosciences, Inc.

SPRBSpruce Biosciences, Inc.$56.50-0.12%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

RXTRackspace Technology

RXTRackspace Technology$5.49+0.56%

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares$15.62+0.08%

NOKNokia

NOKNokia$12.82+0.04%

RKLBRocket Lab

RKLBRocket Lab$105.47+0.34%

POETPoet Technologies

POETPoet Technologies$10.95+0.14%

TQQQProShares Trust - ProShares UltraPro Qqq

TQQQProShares Trust - ProShares UltraPro Qqq$76.28+0.07%

MUMicron Technology

MUMicron Technology$746.81+0.15%

Questions About OTLK

What is the current price of Outlook Therapeutics?

Outlook Therapeutics is trading at $0.22 per share.

What is the 52-week range for Outlook Therapeutics?

Over the past 52 weeks, Outlook Therapeutics has traded between $0.16 and $3.39.

How much debt does Outlook Therapeutics have?

As of the most recent reporting period, Outlook Therapeutics reported total debt of $36.89M.

How much cash does Outlook Therapeutics have on hand?

Outlook Therapeutics reported $8.68M in cash and cash equivalents in its most recent financial results.

What is Outlook Therapeutics’s dividend yield?

Outlook Therapeutics does not currently have a dividend yield.

Outlook Therapeutics

Outlook Therapeutics Financials at a Glance

OTLK News

Outlook Therapeutics Reports Q3 Revenue

Why Shares of Outlook Therapeutics Rose Tuesday

Why Outlook Therapeutics Stock Surged Today

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About Outlook Therapeutics

OTLK Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

Outlook Therapeutics Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About OTLK

What is the current price of Outlook Therapeutics?

What is the 52-week range for Outlook Therapeutics?

How much debt does Outlook Therapeutics have?

How much cash does Outlook Therapeutics have on hand?

What is Outlook Therapeutics’s dividend yield?

Premium Investing Services